CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 déc. 2024 16h05 HE
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Pricing of Public Offering
12 déc. 2024 20h19 HE
|
CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Proposed Public Offering
11 déc. 2024 06h17 HE
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
06 déc. 2024 08h00 HE
|
CG Oncology Inc.
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05 déc. 2024 07h00 HE
|
CG Oncology Inc.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
20 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
11 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30 août 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
18 juin 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec